Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.51%GBPTRY+0.41%AUDCHF+0.41%USDCAD-0.40%NZDCHF+0.39%EURCAD-0.34%GBPHKD+0.32%GBPUSD+0.31%CADJPY+0.29%GBPMXN-0.28%CHFJPY-0.28%USDTRY+0.28%EURCHF+0.26%AUDSGD+0.25%NZDSGD+0.24%NZDUSD+0.23%USDNOK-0.22%EURGBP-0.21%AUDUSD+0.21%NZDCAD-0.21%GBPJPY+0.20%USDCHF+0.19%GBPSGD+0.19%AUDCAD-0.19%USDZAR-0.18%NZDMXN+0.17%USDSEK-0.17%USDPLN-0.17%EURSGD+0.16%USDILS+0.16%CHFSGD+0.15%SGDJPY-0.15%EURHKD+0.12%USDDKK-0.12%EURAUD-0.11%NZDJPY+0.11%GBPAUD+0.11%AUDJPY+0.11%CHFNOK-0.11%NOKJPY+0.11%EURNZD-0.10%EURNOK-0.10%USDJPY-0.10%EURCNH+0.09%AUDDKK+0.09%EURUSD+0.08%GBPCAD-0.08%GBPNZD+0.08%CHFSEK-0.06%PLNJPY+0.06%USDTHB+0.06%EURZAR-0.05%EURSEK-0.05%EURPLN-0.05%USDSGD+0.05%USDCOP-0.04%GBPZAR-0.03%USDMXN-0.03%USDCNH-0.03%EURCZK+0.01%EURJPY-0.01%AUDNZD+0.01%AUDNOK-0.01%USDHKD+0.01%EURDKK0.00%COTTON+0.97%HG1+0.72%XNGUSD+0.44%S1+0.37%W1-0.28%UKOIL-0.28%USOIL-0.22%XPTUSD-0.15%XAGUSD-0.06%GAGUSD-0.06%C1-0.05%GAUUSD-0.04%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.01%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.80%ZECUSDT+8.47%DOGEUSD+14.12%XMRUSDT+5.42%LINKUSD+13.42%XLMUSD-0.06%BCHUSDT+5.33%UNIUSD+7.42%LTCUSD+9.66%SUIUSD+3.23%HBARUSDT+0.18%TONUSD+26.15%TAOUSDT+3.38%AAVEUSD+3.30%DOTUSDT-0.45%ICPUSDT+0.17%ONDOUSDT+0.19%WLDUSDT-0.60%ARBUSDT+6.37%JUPUSDT+0.62%ATOMUSDT+1.29%INJUSDT+13.43%STXUSDT+6.52%FETUSDT+2.08%TIAUSDT+8.81%PYTHUSDT+0.62%SEIUSDT+4.57%IMXUSDT+0.06%OPUSDT+19.70%GRTUSDT+3.86%IOTAUSDT+0.60%WIFUSDT+2.21%AXSUSDT-1.66%POLUSDT+2.60%FARTCOINUSDT+0.63%EOSUSDT+1.66%DYDXUSDT+3.87%GALAUSDT-1.87%ORDIUSDT-0.21%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.51%GBPTRY+0.41%AUDCHF+0.41%USDCAD-0.40%NZDCHF+0.39%EURCAD-0.34%GBPHKD+0.32%GBPUSD+0.31%CADJPY+0.29%GBPMXN-0.28%CHFJPY-0.28%USDTRY+0.28%EURCHF+0.26%AUDSGD+0.25%NZDSGD+0.24%NZDUSD+0.23%USDNOK-0.22%EURGBP-0.21%AUDUSD+0.21%NZDCAD-0.21%GBPJPY+0.20%USDCHF+0.19%GBPSGD+0.19%AUDCAD-0.19%USDZAR-0.18%NZDMXN+0.17%USDSEK-0.17%USDPLN-0.17%EURSGD+0.16%USDILS+0.16%CHFSGD+0.15%SGDJPY-0.15%EURHKD+0.12%USDDKK-0.12%EURAUD-0.11%NZDJPY+0.11%GBPAUD+0.11%AUDJPY+0.11%CHFNOK-0.11%NOKJPY+0.11%EURNZD-0.10%EURNOK-0.10%USDJPY-0.10%EURCNH+0.09%AUDDKK+0.09%EURUSD+0.08%GBPCAD-0.08%GBPNZD+0.08%CHFSEK-0.06%PLNJPY+0.06%USDTHB+0.06%EURZAR-0.05%EURSEK-0.05%EURPLN-0.05%USDSGD+0.05%USDCOP-0.04%GBPZAR-0.03%USDMXN-0.03%USDCNH-0.03%EURCZK+0.01%EURJPY-0.01%AUDNZD+0.01%AUDNOK-0.01%USDHKD+0.01%EURDKK0.00%COTTON+0.97%HG1+0.72%XNGUSD+0.44%S1+0.37%W1-0.28%UKOIL-0.28%USOIL-0.22%XPTUSD-0.15%XAGUSD-0.06%GAGUSD-0.06%C1-0.05%GAUUSD-0.04%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.01%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.80%ZECUSDT+8.47%DOGEUSD+14.12%XMRUSDT+5.42%LINKUSD+13.42%XLMUSD-0.06%BCHUSDT+5.33%UNIUSD+7.42%LTCUSD+9.66%SUIUSD+3.23%HBARUSDT+0.18%TONUSD+26.15%TAOUSDT+3.38%AAVEUSD+3.30%DOTUSDT-0.45%ICPUSDT+0.17%ONDOUSDT+0.19%WLDUSDT-0.60%ARBUSDT+6.37%JUPUSDT+0.62%ATOMUSDT+1.29%INJUSDT+13.43%STXUSDT+6.52%FETUSDT+2.08%TIAUSDT+8.81%PYTHUSDT+0.62%SEIUSDT+4.57%IMXUSDT+0.06%OPUSDT+19.70%GRTUSDT+3.86%IOTAUSDT+0.60%WIFUSDT+2.21%AXSUSDT-1.66%POLUSDT+2.60%FARTCOINUSDT+0.63%EOSUSDT+1.66%DYDXUSDT+3.87%GALAUSDT-1.87%ORDIUSDT-0.21%RONINUSDT-3.42%NOTUSDT+1.21%
IM

Immunome, Inc. (IMNM)

NASDAQ • Healthcare

$17.57
-$1.57 (-8.2%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$19.06
Day Range$17.43 - $19.16
Avg. Volume (3M)1.5M
Market Cap$1.6B
52 Week Range
$13.94$30.06
Next EarningsIn 22 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$254.3M
EPS (TTM)
-$2.54
ROA (TTM)
-44.98%
Current Ratio
15.08

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-27.1%Q1 2026-$0.75
+20.0%Q2 2026-$0.48
-26.5%Q3 2026-$0.65
Next

Nov 5

in 22 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -26.5%

Immunome’s preliminary results for the second fiscal quarter of 2026 trailed expectations on EPS, with -$0.65 versus an estimate of -$0.51 (difference -$0.14), when it reported on August 11, 2026. The quarter’s GAAP net loss widened to about -$73.1 million, down 68.5% from about -$43.4 million a year ago, and operating income was about -$78.1 million as the company continued investing across its oncology pipeline, including antibody-drug conjugates and programs such as Varegacestat and IM-1021. On a per-share basis, EPS of -$0.65 compared with -$0.50 a year earlier (YoY -30.0%). Cash use remained elevated, with negative operating cash flow of roughly -$61.7 million. For the next period, consensus calls for EPS of -$0.64 on revenue of $181,818.00.

Next report — what to expect

Immunome, Inc. (IMNM) reports earnings on November 5, 2026. Wall Street is looking for EPS of -$0.65 on revenue of $166,667.00. For trailing context, revenue was -100.0% year over year last quarter. Immunome has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Immunome, Inc.

Immunome, Inc. (NASDAQ: IMNM) is a Biotechnology company in the healthcare sector developing oncology therapeutics in the United States. The company is a small-cap drug developer focused on antibody-drug conjugates and related cancer programs, with Varegacestat, IM-1021, and other pipeline assets spanning clinical and preclinical stages.

Name
Immunome, Inc.
CEO
Clay Siegall
Website
www.immunome.com
Industry
Healthcare
Year Founded
2006
Employees
247

Today's Snapshot

AI-generated

IMNM closed 8.2% below yesterday's close, in line with a weaker sector. Trading was busier than usual, with volume about half as much again as its usual level.

Trading Volume

Above 10d avg 1.4M

2M

vs S&P 500 Today

Strong Underperformance

-8.18%

Updated: October 13, 2026 at 20:27 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
IMNM, at roughly 17.6, shows a strong-sell technical profile characterized by clear downward momentum and pronounced trend strength. ADX above 34 denotes a strong directional move, while bearish momentum is indicated by a negative MACD and declining short-term momentum despite oversold RSI and stochastic readings. The market trades beneath its short- and medium-term averages and well below the 200-day level, and ATR near 6.5% reflects elevated volatility. Large negative OBV and pivot resistance above the price reinforce distribution. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$19.80 - $23.08
    Sell
  • RSI (14)23.65
    Buy
  • Stochastic %K (14, 3, 3)8.18
    Buy
  • MACD Level (12, 26)-1.76
    Sell

Peers & Related Assets

SLSSELLAS Life Sciences Group, Inc.
$12.41+4.0%
CLDXCelldex Therapeutics, Inc.
$28.25-4.0%
CRVSCorvus Pharmaceuticals, Inc.
$9.41-6.4%
AVBPArriVent BioPharma, Inc.
$16.09-2.3%
IMCRImmunocore Holdings plc
IMTXImmatics N.V.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.